GWT-TUD GmbH
Quick facts
Marketed products
- Acnatac® Gel left face · Dermatology
Acnatac® Gel combines clindamycin (an antibiotic) and benzoyl peroxide (an antimicrobial oxidizing agent) to reduce acne-causing bacteria and inflammation on the skin. - Acnatac® Gel right face · Dermatology
Acnatac® Gel combines clindamycin (an antibiotic) and benzoyl peroxide (an antimicrobial and keratolytic agent) to reduce acne-causing bacteria and promote skin cell turnover. - Epiduo® Gel left face
- Epiduo® Gel right face · Dermatology
Epiduo combines adapalene (a retinoid) and benzoyl peroxide to reduce acne by normalizing skin cell turnover and killing acne-causing bacteria. - pazopanib or guideline conform chemotherapy · Oncology
Pazopanib is a multi-targeted tyrosine kinase inhibitor that blocks angiogenesis and tumor cell proliferation by inhibiting VEGFR, PDGFR, and c-Kit signaling. - Secukinumab 300 mg
Phase 3 pipeline
- e.-coli-nissle · Gastroenterology
E. coli Nissle is a probiotic bacterium that modulates the gut microbiome to exert its therapeutic effects. - nicotine acid · Cardiovascular
Nicotine acid, also known as niacin, primarily functions by reducing the production of very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) cholesterol in the liver.
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: